Edgewise Therapeutics, Inc. — 2022 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2022; the filing was signed February 23, 2023. This is an annual report, not a standalone fourth-quarter report, and it does not provide separate Q4 financial results. Edgewise is a clinical-stage biotechnology company developing treatments for rare muscle disorders. It has no approved products and has generated no revenue.
Its lead candidate, EDG-5506, is in Phase 2 trials for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). EDG-7500, a candidate for hypertrophic cardiomyopathy, remained in preclinical/IND-enabling work; the company planned to file an IND in Q3 2023. The company retained global development and commercialization rights to its programs.
Financial and operating metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $54.0 million | $32.2 million |
| General and administrative expense | $17.6 million | $11.0 million |
| Total operating expenses | $71.7 million | $43.2 million |
| Net loss | $67.6 million | $42.8 million |
| Basic and diluted net loss per share | $1.26 | $1.14 |
| Net cash used in operating activities | $52.6 million | $33.5 million |
| Cash, cash equivalents and marketable securities at year-end | $351.9 million | $280.7 million |
Gross profit and margins are not applicable because the company had no product revenue. Cash provided by financing was $129.6 million, primarily from the September 2022 follow-on offering, which generated $129.2 million net. Cash used in investing activities was $70.6 million, including purchases of marketable securities and facility equipment/improvements. The company reported no borrowings; total liabilities were $20.4 million, including $4.4 million of operating lease liabilities. Accumulated deficit was $144.6 million.
Material changes versus the prior comparable period
- Net loss increased by $24.8 million year over year. R&D expense rose by $21.8 million, reflecting increased EDG-5506 trial and manufacturing costs, EDG-7500 and discovery work, and personnel-related costs.
- G&A expense increased by $6.6 million, including higher personnel, public-company, professional-services and insurance costs.
- Interest income increased to $4.0 million from $0.4 million, driven by higher interest rates and larger invested balances.
- Operating cash use increased by $19.1 million. Year-end cash, cash equivalents and marketable securities rose by $71.2 million, supported by the follow-on offering.
- Shares outstanding increased to 63.3 million from 49.5 million at year-end 2021, primarily reflecting the follow-on offering and other equity issuances.
Outlook, management commentary and risks
- Management said year-end liquidity was expected to fund the current operating plan for at least 12 months from the financial-statement issuance date. The company nevertheless expects substantial ongoing losses and says further capital will be needed to develop candidates and pursue commercialization. Funding availability and timing are uncertain; additional equity could dilute shareholders.
- Management expected R&D spending to increase as EDG-5506 advances and EDG-7500 and other programs progress. Planned milestones included reporting 12-month ARCH BMD data in Q2 2023, potentially amending CANYON to add a registration-enabling cohort in the second half of 2023, and initiating EDG-7500 Phase 1 in the second half of 2023 subject to IND clearance.
- In the six-month open-label ARCH study, EDG-5506 was reported as generally well tolerated, with reductions in muscle-damage biomarkers and positive trends in functional measures. These interim, small-sample, uncontrolled results are not evidence of established clinical benefit; the Phase 2 trials are intended to provide further evidence.
- Key risks include clinical and regulatory failure or delay, uncertain translation of preclinical and early clinical findings, patient-enrollment challenges in rare diseases, competition, dependence on third-party manufacturers and CROs, and lack of redundant supply arrangements. COVID-19 had previously disrupted trial enrollment, operations and supply activities; broader macroeconomic, inflation and geopolitical effects also remain uncertain.
- The company reported no material legal proceedings. Under the OSIF license, it may owe development/regulatory milestones of up to $1.3 million per covered product, sales milestones of approximately $2.3 million per covered product, and low-single-digit royalties if applicable. A 2023 lease expansion adds approximately $1.7 million of future minimum payments.
Most important facts for investors to verify
- Review forthcoming controlled-trial results for EDG-5506, including functional outcomes, safety, durability and whether biomarker changes translate into meaningful patient benefit.
- Check actual cash burn against the stated runway, and monitor financing needs, equity issuance and share-count dilution.
- Confirm progress and timing for the CANYON and LYNX trials, any registration-enabling design, and EDG-7500 IND and Phase 1 plans.
- Assess manufacturing capacity, supply redundancy, regulatory requirements and intellectual-property protection as programs advance.
- Verify the audited financial statements and note that KPMG’s audit opinion covered the financial statements, not internal-control effectiveness; management reported controls effective, but the auditor did not provide an attestation.